Related Experiment Video
Updated: May 19, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Giant cell myocarditis. Diagnosis and treatment
1Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, 55905, Rochester, MN, USA. cooper.leslie@mayo.edu
Insights
Giant cell myocarditis (GCM) is a rare heart condition often presenting as severe heart failure. Early diagnosis via biopsy and immunosuppression improve outcomes, but recurrence is a concern.
Area of Science:
- Cardiology
- Immunology
- Pathology
Background:
- Giant cell myocarditis (GCM) typically manifests as acute dilated cardiomyopathy resistant to standard treatments.
- Significant proportions of GCM patients experience ventricular tachycardia and heart block.
Purpose of the Study:
- To review the clinical presentation, diagnosis, treatment, and outcomes of Giant Cell Myocarditis.
- To highlight the underlying mechanisms and management challenges of GCM.
Main Methods:
- Review of recent studies on GCM pathophysiology, clinical features, and treatment strategies.
- Analysis of diagnostic approaches including endomyocardial biopsy.
- Examination of outcomes data, including transplantation and recurrence rates.
Main Results:
- Endomyocardial biopsy aids GCM diagnosis, enabling immunosuppressive therapy and mechanical support.
- Cytokine-induced changes in desmosomal proteins may mediate GCM-related arrhythmias.
- Inflammatory pathway regulation in GCM differs from lymphocytic myocarditis.
- Heart transplantation is effective, but GCM recurrence occurs in 20-25% of allografts and up to 8 years in native hearts.
Conclusions:
- Prompt diagnosis and immunosuppression are crucial for managing GCM.
- Understanding GCM's unique inflammatory profile is key.
- Long-term management strategies for recovered GCM patients require further investigation through multicenter studies.
Abstract:
Giant cell myocarditis (GCM) usually presents as acute dilated cardiomyopathy that does not improve with guideline-based treatments. Ventricular tachycardia and heart block occur in a substantial number of patients. Diagnosis by endomyocardial biopsy can allow for the addition of immunosuppressive therapy and timely use of mechanical circulatory support when indicated. Recent studies suggest that the ventricular arrhythmias in GCM may be mediated by a cytokine-induced change in desmosomal protein expression. Genomic and proteomic studies suggest that the regulation of inflammatory pathways differs in GCM from lymphocytic myocarditis. Transplantation remains an effective therapy despite a 20-25% risk of GCM recurrence in the allograft. Recurrence in the native heart occurs up to 8 years after initial diagnosis. The long-term management of GCM patients, who initially recover, is not known and highlights the need for continuing multicenter collaborative clinical investigations.
Related Concept Videos
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis III: Medical Management
Myocarditis IV: Nursing Management
Myocarditis I: Introduction
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
